In addition, it should be noted that a substantial proportion of the rising costs of diabetes care in the U.S. is attributed to insulin, and newer diabetes medications are also quite costly.[5, 23] Determining the incremental benefit of continuing newer diabetes medication when starting insulin will be important for achieving high value care of patients with type 2 diabetes. Here, INS is linked to diabetes mellitus.